Related Experiment Video
Updated: May 31, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Beyond Dopamine: Novel Therapeutic Pathways for Parkinson's Disease Through Receptor Signaling
Rashmi Bhushan1, Falguni Goel1, Shamsher Singh1
1Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab 142001, India.
Abstract:
Parkinson's disease (PD) is a progressive neurological condition characterized by both dopaminergic and non-dopaminergic brain cell loss. Patients with Parkinson's disease have tremors as a result of both motor and non-motor symptoms developing. Idiopathic Parkinson's disease (idiopathic PD) prevalence is increasing in people over 60. The medication L-dopa, which is now on the market, merely relieves symptoms and has several negative effects. In this article, we highlight the therapeutic potential of glucagon-like peptide-1, adenosine A2A, and cannabinoid receptors as attractive targets for enhancing neuroprotection and reducing a variety of motor and non-motor symptoms. Recent research has widened knowledge of new therapeutic targets and detailed cellular mechanisms, providing invaluable insights into the essential roles of cannabinoid receptors, adenosine A2A receptors, and glucagon-like peptide-1 receptors in PD pathogenesis and unique opportunities for drug development for mankind globally.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Drugs Affecting Neurotransmitter Synthesis
Amplifying Signals via Enzymatic Cascade

